{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:48Z","timestamp":1791305148018,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41375-022-01563-8","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T14:04:18Z","timestamp":1649772258000},"page":"1646-1653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Khvedelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Romejko-Jarosinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ma\u2019koseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"G\u00fclbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Hamladji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Alma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Halaburda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida Botelho","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9725","authenticated-orcid":false,"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.1993.11.4.704","volume":"11","author":"M Crump","year":"1993","unstructured":"Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin\u2019s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704\u201311.","journal-title":"J Clin Oncol."},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","volume":"17","author":"M Andre","year":"1999","unstructured":"Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: a case- control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999;17:222\u20139.","journal-title":"J Clin Oncol"},{"key":"1563_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet."},{"key":"1563_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.6004\/jnccn.2011.0087","volume":"9","author":"L Holmberg","year":"2011","unstructured":"Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1060\u201371.","journal-title":"J Natl Compr Canc Netw"},{"key":"1563_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2004-12-4689","volume":"106","author":"JC Lavoie","year":"2005","unstructured":"Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106:1473\u20138.","journal-title":"Blood."},{"key":"1563_CR6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet."},{"key":"1563_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","volume":"17","author":"HM Lazarus","year":"1999","unstructured":"Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin\u2019s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534\u201345.","journal-title":"J Clin Oncol"},{"key":"1563_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531\u20133.","journal-title":"Leuk Lymphoma"},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/bmt.2013.226","volume":"49","author":"MA Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant. 2014;49:599\u2013606.","journal-title":"Bone Marrow Transplant"},{"key":"1563_CR10","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","volume":"24","author":"C Martinez","year":"2013","unstructured":"Martinez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, et al. Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430\u20134.","journal-title":"Ann Oncol"},{"key":"1563_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","volume":"146","author":"AJ Moskowitz","year":"2009","unstructured":"Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro- Malaspina H, Zhang Z, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146:158\u201363.","journal-title":"Br J Haematol."},{"key":"1563_CR12","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","volume":"365","author":"KS Peggs","year":"2005","unstructured":"Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin\u2019s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934\u201341.","journal-title":"Lancet."},{"key":"1563_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","volume":"12","author":"I Alvarez","year":"2006","unstructured":"Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12:172\u201383.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.13441","volume":"94","author":"SP Robinson","year":"2009","unstructured":"Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230\u20138.","journal-title":"Haematologica."},{"key":"1563_CR15","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671\u20137.","journal-title":"Blood."},{"key":"1563_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR- ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310\u20137.","journal-title":"Haematologica"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"1563_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","volume":"125","author":"AK Gopal","year":"2015","unstructured":"Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236\u201343.","journal-title":"Blood."},{"key":"1563_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15152","volume":"181","author":"A Bazarbachi","year":"2018","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;181:86\u201396.","journal-title":"Br J Haematol."},{"key":"1563_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med."},{"key":"1563_CR21","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733\u20139.","journal-title":"J Clin Oncol."},{"key":"1563_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"1563_CR23","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood 2017;129:1380\u20138.","journal-title":"Blood"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","volume":"14","author":"LM Burroughs","year":"2008","unstructured":"Burroughs LM, O\u2019Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279\u201387.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1563_CR25","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"C Martinez","year":"2017","unstructured":"Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425\u201332.","journal-title":"J Clin Oncol"},{"key":"1563_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2014;49:190\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"1563_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","volume":"4","author":"T Badar","year":"2020","unstructured":"Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4:47\u201354.","journal-title":"Blood Adv."},{"key":"1563_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10428190601183769","volume":"48","author":"BD Cheson","year":"2007","unstructured":"Cheson BD. Overcoming mechanisms of RECISTance in lymphoma. Leuk Lymphoma. 2007;48:447\u20138.","journal-title":"Leuk Lymphoma."},{"key":"1563_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"1563_CR30","volume-title":"R: a language for statistical computing","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: a language for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014."},{"key":"1563_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.20.01447","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Hamadani M. Is There still a role for allogeneic transplantation in the management of lymphoma? J Clin Oncol. 2021;39:487\u201398.","journal-title":"J Clin Oncol"},{"key":"1563_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","volume":"52","author":"J El Cheikh","year":"2017","unstructured":"El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan- Dabaja MA, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1074\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1563_CR33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"1563_CR34","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"1563_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47\u201356.","journal-title":"Eur J Cancer"},{"key":"1563_CR36","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","volume":"35","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35:2672\u201383.","journal-title":"Leukemia."},{"key":"1563_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07602-w","volume":"20","author":"L Castagna","year":"2020","unstructured":"Castagna L, Busca A, Bramanti S, Raiola Anna M, Malagola M, Ciceri F, et al. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer. 2020;20:1140.","journal-title":"BMC Cancer"}],"updated-by":[{"DOI":"10.1038\/s41375-022-01639-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01563-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T12:04:29Z","timestamp":1657886669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01563-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-022-01639-5","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-022-01639-5","URL":"https:\/\/doi.org\/10.1038\/s41375-022-01639-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}